Form 4: Kalaris Therapeutics Director Acquires 18,000 Stock Options
SEC Form 4 Filing
Srinivas Akkaraju, a director and 10% owner of Kalaris Therapeutics, acquired 18,000 stock options on April 10, 2025.
Summary
- On April 10, 2025, Srinivas Akkaraju, a director and 10% owner of Kalaris Therapeutics, acquired 18,000 stock options.
- The options have an exercise price of $7.31.
- The options vest in equal monthly installments over three years, starting from March 18, 2025, and ending on March 18, 2028, contingent upon continuous service.
- The options expire on April 9, 2035.
Sentiment
Score: 5
Explanation: This is a neutral event, simply reporting the grant of stock options. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This is a standard Form 4 filing, indicating a change in beneficial ownership of securities by a company insider. It's a routine part of corporate governance and transparency.
Stakeholder Impact
- The acquisition of stock options by a director could be perceived positively by shareholders as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| March 18, 2025 | Start date for monthly vesting of options. |
| April 10, 2025 | Date of transaction: Acquisition of stock options. |
| April 11, 2025 | Date of filing. |
| March 18, 2028 | End date for monthly vesting of options. |
| April 9, 2035 | Expiration date of the options. |
Keywords
Kalaris Therapeutics, Stock Options, Form 4, Director, Beneficial Ownership, KLRS, Equity Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.